ClinicalTrials.gg
RecruitingNCT06682780Updated Aug 28, 2026

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

A Phase 1/2 interventional study of LM-2417 and Docetaxel in Advanced Solid Tumor, sponsored by LaNova Medicines Limited. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
320
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing to participate in the study and sign the form (ICF) prior to any procedure.
  2. Aged 18-80 years old (including boundary values) , male or female.
  3. (ECOG) performance status of 0-1.
  4. ≥ 3 months.
  5. Subjects must have histological or cytological confirmation of recurrent or advanced solid tumors, or currently lack or are intolerant of, standard therapy.
  6. Subjects must have Archived Samples or fresh tumor tissue specimens are required for testing.
  7. At least one evaluable lesion.
  8. Subjects must show appropriate organ and marrow function inlaboratory examinations within 7 days prior to the first dose.
  9. Women of (WOCBP) must agree to use highly effective methods of prior to study entry, during the study and for 6 months after the last dose of study drug.
  10. Subjects who can communicate well with investigators and understand and adhere to the requirements of this study.

Single-agent dose of 6mg/kg, 12mg/kg and and combined cohort:Subjects tested positive for biomarkers.

Exclusion criteria

Exclusion Criteria:

  1. Previously received with same target therapy.
  2. Subjects has participated in any other interventional clinical trial within 28 days prior to the first dosing of LM-2417.
  3. Subjects with anti-tumor treatment within 21 days prior to the first dosing of LM-2417, including radiotherapy, chemotherapy, endocrine therapy, and immunotherapy, etc.
  4. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of v5.0.
  5. Poorly controlled tumor-related pain.
  6. Subjects with symptomatic/active central nervous system (CNS).
  7. Subject who have uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  8. Subjects with known to antibody therapy;
  9. Subjects who take systemic (> 10 mg daily prednisone equivalents) for more than 7 days or other systemic medications within 2 weeks prior to the first dosing of LM-2417.
  10. Previous or current known disease.
  11. Subject who has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.
  12. Use of any or live attenuated vaccines within 28 days prior to the first dosing of LM-2417.;
  13. Subjects who are using therapeutic doses of anticoagulants such as heparin or vitamin K antagonists.
  14. Subjects who received major surgery or interventional treatment within28 days prior to the first dosing of LM-2417.
  15. Subject who have history of severe cardiovascular disease.
  16. Subjects who have uncontrolled or severe illness.
  17. infection, active or infection.
  18. Subjects who have other active invasive cancers, other than the one treated in this trial, within 5 years prior to screening.
  19. female who have positive results in pregnancy test or are lactating.
  20. Subject who have a known psychiatric diseases or disorders that may affect compliance with the trial.
  21. Subject who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    LM2417 Dose Escalation(Q2W/Q3W)

    Drug: LM-2417

  • Experimental
    LM-2417 combination therapy exploratory

    Drug: LM-2417 · Drug: Docetaxel · Drug: Toripalimab/Tirelizumab · Drug: Carboplatin · Drug: Niraparib · Drug: Lenvatinib

  • Experimental
    LM-2417 combination expansion

    Drug: LM-2417 · Drug: Docetaxel · Drug: Toripalimab/Tirelizumab · Drug: Carboplatin · Drug: Niraparib · Drug: Lenvatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Phase I/II

    Time frame: 60 weeks

  2. Incidence of dose-limitingtoxicity (DLT)

    Phase I/II

    Time frame: 60 weeks

  3. Incidence of serious adverse event (SAE)

    Phase I/II

    Time frame: 60 weeks

  4. Temperatures

    Phase I/II

    Time frame: 60 weeks

  5. Pulse in BPM(Beat per Minute)

    Phase I/II

    Time frame: 60 weeks

  6. Blood Pressure in mmHg

    Phase I/II

    Time frame: 60 weeks

  7. Weight in Kg

    Phase I/II

    Time frame: 60 weeks

  8. Height in centimeter

    Phase I/II

    Time frame: 60 weeks

  9. Laboratory tests-Blood Routine examination

    Phase I/II

    Time frame: 60 weeks

  10. Laboratory tests-Urine Routine test

    Phase I/II

    Time frame: 60 weeks

  11. Laboratory tests-Blood biochemistry

    Phase I/II

    Time frame: 60 weeks

  12. Laboratory tests- Coangulation function

    Phase I/II

    Time frame: 60 weeks

  13. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase I/II

    Time frame: 60 weeks

  14. 12-lead electrocardiogram (ECG) in HR

    Phase I/II

    Time frame: 60 weeks

  15. 12-lead electrocardiogram (ECG) in RR

    Phase I/II

    Time frame: 60 weeks

  16. 12-lead electrocardiogram (ECG) in PR

    Phase I/II

    Time frame: 60 weeks

  17. 12-lead electrocardiogram (ECG) in QRS

    Phase I/II

    Time frame: 60 weeks

  18. 12-lead electrocardiogram (ECG) in QT

    Phase I/II

    Time frame: 60 weeks

  19. 12-lead electrocardiogram (ECG) in QTcF

    Phase I/II

    Time frame: 60 weeks

  20. ECOG(Eastern Cooperative Oncology Group) score

    Phase I/II

    Time frame: 60 weeks

  21. Overall Response Rate (ORR)

    Phase I/II

    Time frame: 76 weeks

Secondary outcomes

  1. Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

    Phase I/II

    Time frame: 112 weeks

  2. PK Parameter:Time of Maximum Observed Concentration (Tmax)

    Phase I/II

    Time frame: 112 weeks

  3. PK Parameter: Area Under the Concentration-time Curve(AUC)

    Phase I/II

    Time frame: 112 weeks

  4. PK Parameter: Steady State Maximum Concentration(Cmax,ss) PK Parameter: Steady State Maximum Concentration(Cmax,ss)

    Phase I/II

    Time frame: 112 weeks

  5. PK Parameter: Steady State Minimum Concentration(Cmin,ss)

    Phase I/II

    Time frame: 112 weeks

  6. PK Parameter: Systemic Clearance at Steady State (CLss)

    Phase I/II

    Time frame: 112 weeks

  7. PK Parameter: Accumulation Ratio (Rac)

    Phase I/II

    Time frame: 112 weeks

  8. PK Parameter: Elimination Half-life (t1/2)

    Phase I/II

    Time frame: 112 weeks

  9. PK Parameter: Volume of Distribution at Steady-State (Vss)

    Phase I/II

    Time frame: 112 weeks

  10. PK Parameter: Degree of Fluctuation (DF)

    Phase I/II

    Time frame: 112 weeks

  11. Immunogenicity of LM-2417

    Phase I/II

    Time frame: 112 weeks

  12. Biomarker correlation(NaPi2b)

    Phase I/II

    Time frame: 112 weeks

  13. Duration of Response (DOR) in Month

    Phase I/II

    Time frame: 64 weeks

  14. Disease control rate (DCR) in percentage

    Phase I/II

    Time frame: 64 weeks

  15. progression-free survival (PFS) in Month

    Phase I/II

    Time frame: 64 weeks

  16. Safety: AE/SAE (Number of participants with treatment-related adverse events as Overall survival (OS) in Month

    Phase I/II

    Time frame: 64 weeks

  17. Changes of target lesions from baseline in Millimeter

    Phase I/II

    Time frame: 64 weeks

  18. AE/SAE (Number of participants with treatment-related adverse events as assessed by CTCAE v5.0) Safety: AE/SAE (Number of participants with treatment-related adverse events as assessed by CTCAE v5.0)

    Phase I/II

    Time frame: 64 weeks

07

Study locations

1 of 1 sites recruiting
  • FuDan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Xiaohua Wu, Dr · Contact
    • Hongxia Wang · Contact
    • Xiaohua Wu · Principal investigator
    • Hongxia Wang · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2028, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Nov 12, 2024
StartActual
Sep 17, 2025
Primary completionEst.
Dec 25, 2028
CompletionEst.
Dec 1, 2029
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06682780
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Sep 17, 2025
Primary completion
Dec 25, 2028 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Aug 28, 2026

Study contacts

Lingli Zhao
Contact
linglizhao@lanovamed.com
+8618901636324
Paul Kong
Contact
paulkong@lanovamed.com
+8613564682439

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion